CN106075343A - 一种降血脂中西药制剂及其制备方法 - Google Patents
一种降血脂中西药制剂及其制备方法 Download PDFInfo
- Publication number
- CN106075343A CN106075343A CN201610553153.8A CN201610553153A CN106075343A CN 106075343 A CN106075343 A CN 106075343A CN 201610553153 A CN201610553153 A CN 201610553153A CN 106075343 A CN106075343 A CN 106075343A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- blood fat
- fat reducing
- western medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 43
- 239000008280 blood Substances 0.000 title claims abstract description 39
- 239000003814 drug Substances 0.000 title claims abstract description 39
- 210000004369 blood Anatomy 0.000 title claims abstract description 38
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims abstract description 42
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims abstract description 24
- 229960002079 calcium pantothenate Drugs 0.000 claims abstract description 23
- 210000000582 semen Anatomy 0.000 claims abstract description 23
- 150000004676 glycans Chemical class 0.000 claims abstract description 22
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 22
- 239000005017 polysaccharide Substances 0.000 claims abstract description 22
- 229960003512 nicotinic acid Drugs 0.000 claims abstract description 21
- 235000001968 nicotinic acid Nutrition 0.000 claims abstract description 21
- 239000011664 nicotinic acid Substances 0.000 claims abstract description 21
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims abstract description 19
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims abstract description 19
- 229960004844 lovastatin Drugs 0.000 claims abstract description 19
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000004006 olive oil Substances 0.000 claims abstract description 19
- 235000008390 olive oil Nutrition 0.000 claims abstract description 19
- 239000002994 raw material Substances 0.000 claims abstract description 12
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 21
- 229930064664 L-arginine Natural products 0.000 claims description 21
- 235000014852 L-arginine Nutrition 0.000 claims description 21
- 241001247821 Ziziphus Species 0.000 claims description 21
- 239000007788 liquid Substances 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 12
- -1 nicotinoyl Chemical group 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000011248 coating agent Substances 0.000 claims description 8
- 238000000576 coating method Methods 0.000 claims description 8
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 8
- 239000012567 medical material Substances 0.000 claims description 5
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 2
- 240000008620 Fagopyrum esculentum Species 0.000 claims 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 claims 1
- 229910021529 ammonia Inorganic materials 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003921 oil Substances 0.000 claims 1
- 235000019198 oils Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 230000004060 metabolic process Effects 0.000 abstract description 4
- 230000036772 blood pressure Effects 0.000 abstract description 3
- 230000000968 intestinal effect Effects 0.000 abstract description 3
- 238000002372 labelling Methods 0.000 abstract description 3
- 230000037356 lipid metabolism Effects 0.000 abstract description 3
- 235000016709 nutrition Nutrition 0.000 abstract description 3
- 230000001105 regulatory effect Effects 0.000 abstract description 3
- 239000003053 toxin Substances 0.000 abstract description 3
- 231100000765 toxin Toxicity 0.000 abstract description 3
- 230000007102 metabolic function Effects 0.000 abstract description 2
- 239000004475 Arginine Substances 0.000 abstract 1
- 240000008866 Ziziphus nummularia Species 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 235000019504 cigarettes Nutrition 0.000 description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 206010058646 Arcus lipoides Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- 206010048214 Xanthoma Diseases 0.000 description 1
- 206010048215 Xanthomatosis Diseases 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000003035 anti-peroxidant effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种降血脂中西药制剂,其原料按重量份包括:洛伐他汀1‑3份,烟酸2‑10份,泛酸钙1‑3份,烟酰胺1‑4份,L‑精氨酸0.1‑0.4份,大枣多糖1‑5份,橄榄油1‑6份,决明子10‑20份,山楂5‑15份,丹参1‑5份,大黄1‑10份,生姜1‑8份,苦荞1‑8份,葛根5‑10份。本发明还公开了上述降血脂中西药制剂的制备方法。本发明不仅能为人体提供必须的营养成分,还可有效排出积累在肠道内的毒素,可以改善人体代谢机能,加快新陈代谢,调节脂质代谢,提高降血脂、降血压的效果。
Description
技术领域
本发明涉及药学技术领域,尤其涉及一种降血脂中西药制剂及其制备方法。
背景技术
大量研究资料表明,高血脂症是脑卒中、冠心病、心肌梗死、心脏猝死重要的危险因素;另外高血脂症也是促进高血压、糖耐量异常、糖尿病的危险因素;高血脂症还可导致脂肪肝、肝硬化、胆石症、胰腺炎、眼底出血、失明、周围血管疾病、跛行、高尿酸血症。有些原发性和家族性高血脂症患者还可出现腱状、结节状、掌平面及眼眶周围黄色瘤、青年角膜弓等症状。高脂血症是中老年的常见病和多发病,随着人们生活水平的提高和生活习惯的改变,该病的发病率明显增加,发病的年龄也有所提前,严重危害到了人类生命健康。目前,西药调节血脂虽有肯定的疗效,但有不同程度的副作用,且作用靶点单一。目前公认为调脂最有效并广泛应用的西药是他汀类,但费用高,且有肝脏和肌肉毒性等副作用。目前降低高血脂症药中药也有很多,但疗效较差。
发明内容
基于背景技术存在的技术问题,本发明提出了一种降血脂中西药制剂及其制备方法,不仅能为人体提供必须的营养成分,还可有效排出积累在肠道内的毒素,可以改善人体代谢机能,加快新陈代谢,调节脂质代谢,提高降血脂、降血压的效果。
本发明提出的一种降血脂中西药制剂,其原料按重量份包括:洛伐他汀1-3份,烟酸2-10份,泛酸钙1-3份,烟酰胺1-4份,L-精氨酸0.1-0.4份,大枣多糖1-5份,橄榄油1-6份,决明子10-20份,山楂5-15份,丹参1-5份,大黄1-10份,生姜1-8份,苦荞1-8份,葛根5-10份。
优选地,决明子、山楂、丹参、大黄、生姜、苦荞、葛根的重量比为12-18:8-12:2-4:3-7:3-6:3-6:7-8。
优选地,其原料按重量份包括:洛伐他汀1.5-2.5份,烟酸4-8份,泛酸钙1.5-2.5份,烟酰胺2-3份,L-精氨酸0.2-0.3份,大枣多糖2-4份,橄榄油2-5份,决明子12-18份,山楂8-12份,丹参2-4份,大黄3-7份,生姜3-6份,苦荞3-6份,葛根7-8份。
优选地,烟酸、泛酸钙、烟酰胺、L-精氨酸、大枣多糖、山楂的重量比为6:2:2.3:0.25:3:10。
优选地,其原料按重量份包括:洛伐他汀2份,烟酸6份,泛酸钙2份,烟酰胺2.3份,L-精氨酸0.25份,大枣多糖3份,橄榄油3.5份,决明子15份,山楂10份,丹参3份,大黄5份,生姜4份,苦荞5份,葛根7.5份。
本发明还提出的上述降血脂中西药制剂的制备方法,包括如下步骤:将决明子、山楂、丹参、大黄、生姜、苦荞、葛根混合,加水和无水乙醇,升温,浸泡,升高温度,继续浸泡,煎煮,过滤,干燥得到药液;将洛伐他汀、烟酸、泛酸钙、烟酰胺、L-精氨酸、大枣多糖、橄榄油混合均匀,加入药液进行混合均匀,压片,包衣得到降血脂中西药制剂。
优选地,包括如下步骤:将决明子、山楂、丹参、大黄、生姜、苦荞、葛根混合,加药材重量5-10倍水、1-4倍无水乙醇,设置温度至40-50℃,浸泡2-3h,升高温度至60-80℃,继续浸泡20-60min,煎煮50-100min,过滤,干燥至含水量为20-40wt%得到药液;将洛伐他汀、烟酸、泛酸钙、烟酰胺、L-精氨酸、大枣多糖、橄榄油混合均匀,加入药液进行混合均匀,压片,包衣得到降血脂中西药制剂。
本发明中西结合,不仅降血脂效果显著,且几乎无不良反应,费用低,工艺简单;其中的决明子、山楂、丹参、大黄、生姜、苦荞、葛根不仅能为人体提供必须的营养成分,且可有效排出积累在肠道内的毒素,调节脂质代谢,降血脂、降血压,与泛酸钙、烟酰胺、L-精氨酸合用,可以改善人体代谢机能,加快新陈代谢,降脂效果进一步增强;而大枣多糖、山楂配合作用,具有较好的抗氧化活性,且可通过氧化降低血脂水平,两者在体外抗氧化具有正协同作用,在体内的抗脂质过氧化和调血脂均有正协同作用,体内外也是一致的,进一步与洛伐他汀、烟酸、泛酸钙协同作用,降血脂效果极为优异。
具体实施方式
下面,通过具体实施例对本发明的技术方案进行详细说明。
实施例1
本发明提出的一种降血脂中西药制剂,其原料按重量份包括:洛伐他汀1份,烟酸10份,泛酸钙1份,烟酰胺4份,L-精氨酸0.1份,大枣多糖5份,橄榄油1份,决明子20份,山楂5份,丹参5份,大黄1份,生姜8份,苦荞1份,葛根10份。
实施例2
本发明提出的一种降血脂中西药制剂,其原料按重量份包括:洛伐他汀3份,烟酸2份,泛酸钙3份,烟酰胺1份,L-精氨酸0.4份,大枣多糖1份,橄榄油6份,决明子10份,山楂15份,丹参1份,大黄10份,生姜1份,苦荞8份,葛根5份。
本发明还提出的上述降血脂中西药制剂的制备方法,包括如下步骤:将决明子、山楂、丹参、大黄、生姜、苦荞、葛根混合,加水和无水乙醇,升温,浸泡,升高温度,继续浸泡,煎煮,过滤,干燥得到药液;将洛伐他汀、烟酸、泛酸钙、烟酰胺、L-精氨酸、大枣多糖、橄榄油混合均匀,加入药液进行混合均匀,压片,包衣得到降血脂中西药制剂。
实施例3
本发明提出的一种降血脂中西药制剂,其原料按重量份包括:洛伐他汀1.5份,烟酸8份,泛酸钙1.5份,烟酰胺3份,L-精氨酸0.2份,大枣多糖4份,橄榄油2份,决明子18份,山楂8份,丹参4份,大黄3份,生姜6份,苦荞3份,葛根8份。
本发明还提出的上述降血脂中西药制剂的制备方法,包括如下步骤:将决明子、山楂、丹参、大黄、生姜、苦荞、葛根混合,加药材重量5倍水、4倍无水乙醇,设置温度至40℃,浸泡3h,升高温度至60℃,继续浸泡60min,煎煮50min,过滤,干燥至含水量为40wt%得到药液;将洛伐他汀、烟酸、泛酸钙、烟酰胺、L-精氨酸、大枣多糖、橄榄油混合均匀,加入药液进行混合均匀,压片,包衣得到降血脂中西药制剂。
实施例4
本发明提出的一种降血脂中西药制剂,其原料按重量份包括:洛伐他汀2.5份,烟酸4份,泛酸钙2.5份,烟酰胺2份,L-精氨酸0.3份,大枣多糖2份,橄榄油5份,决明子12份,山楂12份,丹参2份,大黄7份,生姜3份,苦荞6份,葛根7份。
本发明还提出的上述降血脂中西药制剂的制备方法,包括如下步骤:将决明子、山楂、丹参、大黄、生姜、苦荞、葛根混合,加药材重量10倍水、1倍无水乙醇,设置温度至50℃,浸泡2h,升高温度至80℃,继续浸泡20min,煎煮100min,过滤,干燥至含水量为20wt%得到药液;将洛伐他汀、烟酸、泛酸钙、烟酰胺、L-精氨酸、大枣多糖、橄榄油混合均匀,加入药液进行混合均匀,压片,包衣得到降血脂中西药制剂。
实施例5
本发明提出的一种降血脂中西药制剂,其原料按重量份包括:洛伐他汀2份,烟酸6份,泛酸钙2份,烟酰胺2.3份,L-精氨酸0.25份,大枣多糖3份,橄榄油3.5份,决明子15份,山楂10份,丹参3份,大黄5份,生姜4份,苦荞5份,葛根7.5份。
本发明还提出的上述降血脂中西药制剂的制备方法,包括如下步骤:将决明子、山楂、丹参、大黄、生姜、苦荞、葛根混合,加药材重量8倍水、3倍无水乙醇,设置温度至45℃,浸泡2.5h,升高温度至70℃,继续浸泡40min,煎煮80min,过滤,干燥至含水量为30wt%得到药液;将洛伐他汀、烟酸、泛酸钙、烟酰胺、L-精氨酸、大枣多糖、橄榄油混合均匀,加入药液进行混合均匀,压片,包衣得到降血脂中西药制剂。
以上所述,仅为本发明较佳的具体实施方式,但本发明的保护范围并不局限于此,任何熟悉本技术领域的技术人员在本发明揭露的技术范围内,根据本发明的技术方案及其发明构思加以等同替换或改变,都应涵盖在本发明的保护范围之内。
Claims (7)
1.一种降血脂中西药制剂,其特征在于,其原料按重量份包括:洛伐他汀1-3份,烟酸2-10份,泛酸钙1-3份,烟酰胺1-4份,L-精氨酸0.1-0.4份,大枣多糖1-5份,橄榄油1-6份,决明子10-20份,山楂5-15份,丹参1-5份,大黄1-10份,生姜1-8份,苦荞1-8份,葛根5-10份。
2.根据权利要求1所述降血脂中西药制剂,其特征在于,决明子、山楂、丹参、大黄、生姜、苦荞、葛根的重量比为12-18:8-12:2-4:3-7:3-6:3-6:7-8。
3.根据权利要求1或2所述降血脂中西药制剂,其特征在于,其原料按重量份包括:洛伐他汀1.5-2.5份,烟酸4-8份,泛酸钙1.5-2.5份,烟酰胺2-3份,L-精氨酸0.2-0.3份,大枣多糖2-4份,橄榄油2-5份,决明子12-18份,山楂8-12份,丹参2-4份,大黄3-7份,生姜3-6份,苦荞3-6份,葛根7-8份。
4.根据权利要求1-3任一项所述降血脂中西药制剂,其特征在于,烟酸、泛酸钙、烟酰胺、L-精氨酸、大枣多糖、山楂的重量比为6:2:2.3:0.25:3:10。
5.根据权利要求1-4任一项所述降血脂中西药制剂,其特征在于,其原料按重量份包括:洛伐他汀2份,烟酸6份,泛酸钙2份,烟酰胺2.3份,L-精氨酸0.25份,大枣多糖3份,橄榄油3.5份,决明子15份,山楂10份,丹参3份,大黄5份,生姜4份,苦荞5份,葛根7.5份。
6.一种如权利要求1-5任一项所述降血脂中西药制剂的制备方法,其特征在于,包括如下步骤:将决明子、山楂、丹参、大黄、生姜、苦荞、葛根混合,加水和无水乙醇,升温,浸泡,升高温度,继续浸泡,煎煮,过滤,干燥得到药液;将洛伐他汀、烟酸、泛酸钙、烟酰胺、L-精氨酸、大枣多糖、橄榄油混合均匀,加入药液进行混合均匀,压片,包衣得到降血脂中西药制剂。
7.根据权利要求6所述包括如下步骤:所述降血脂中西药制剂的制备方法,其特征在于,包括如下步骤:将决明子、山楂、丹参、大黄、生姜、苦荞、葛根混合,加药材重量5-10倍水、1-4倍无水乙醇,设置温度至40-50℃,浸泡2-3h,升高温度至60-80℃,继续浸泡20-60min,煎煮50-100min,过滤,干燥至含水量为20-40wt%得到药液;将洛伐他汀、烟酸、泛酸钙、烟酰胺、L-精氨酸、大枣多糖、橄榄油混合均匀,加入药液进行混合均匀,压片,包衣得到降血脂中西药制剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610553153.8A CN106075343A (zh) | 2016-07-14 | 2016-07-14 | 一种降血脂中西药制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610553153.8A CN106075343A (zh) | 2016-07-14 | 2016-07-14 | 一种降血脂中西药制剂及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106075343A true CN106075343A (zh) | 2016-11-09 |
Family
ID=57220300
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610553153.8A Pending CN106075343A (zh) | 2016-07-14 | 2016-07-14 | 一种降血脂中西药制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106075343A (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107441478A (zh) * | 2017-10-11 | 2017-12-08 | 苏州和必尔斯电子科技有限公司 | 一种治疗慢性肠胃炎的药物组合物及其制备方法 |
CN107670011A (zh) * | 2017-11-08 | 2018-02-09 | 罗昌兴 | 一种降血脂的中西药制剂及其制备方法 |
CN107693598A (zh) * | 2017-11-08 | 2018-02-16 | 罗昌兴 | 一种降血脂的复方制剂及其制备方法 |
CN115429884A (zh) * | 2022-10-20 | 2022-12-06 | 黑龙江乌苏里江制药有限公司 | 一种预防或治疗高脂血症的联合用药物组合物及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101628041A (zh) * | 2008-07-14 | 2010-01-20 | 河南大学 | 大枣降血脂有效部位及其提取方法和应用 |
CN104857506A (zh) * | 2015-05-15 | 2015-08-26 | 张家港市五湖新材料技术开发有限公司 | 一种降血脂中药及制备方法 |
CN105031404A (zh) * | 2015-08-21 | 2015-11-11 | 吕欢 | 一种减肥降脂的中西药复方制剂 |
CN105616481A (zh) * | 2016-03-03 | 2016-06-01 | 广东福寿仙生物科技有限公司 | 一种降血脂中西药制剂及其制备方法 |
-
2016
- 2016-07-14 CN CN201610553153.8A patent/CN106075343A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101628041A (zh) * | 2008-07-14 | 2010-01-20 | 河南大学 | 大枣降血脂有效部位及其提取方法和应用 |
CN104857506A (zh) * | 2015-05-15 | 2015-08-26 | 张家港市五湖新材料技术开发有限公司 | 一种降血脂中药及制备方法 |
CN105031404A (zh) * | 2015-08-21 | 2015-11-11 | 吕欢 | 一种减肥降脂的中西药复方制剂 |
CN105616481A (zh) * | 2016-03-03 | 2016-06-01 | 广东福寿仙生物科技有限公司 | 一种降血脂中西药制剂及其制备方法 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107441478A (zh) * | 2017-10-11 | 2017-12-08 | 苏州和必尔斯电子科技有限公司 | 一种治疗慢性肠胃炎的药物组合物及其制备方法 |
CN107670011A (zh) * | 2017-11-08 | 2018-02-09 | 罗昌兴 | 一种降血脂的中西药制剂及其制备方法 |
CN107693598A (zh) * | 2017-11-08 | 2018-02-16 | 罗昌兴 | 一种降血脂的复方制剂及其制备方法 |
CN115429884A (zh) * | 2022-10-20 | 2022-12-06 | 黑龙江乌苏里江制药有限公司 | 一种预防或治疗高脂血症的联合用药物组合物及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101090284B1 (ko) | 홍삼과 녹용 추출물을 포함하는 드링크제 및 그의 제조방법 | |
RU2352147C2 (ru) | Биологически активная добавка (варианты) | |
CN106075343A (zh) | 一种降血脂中西药制剂及其制备方法 | |
CN103609766B (zh) | 一种具有修身美容养颜功能的泡袋剂 | |
RU2429001C1 (ru) | Средство "таблетки для ума" | |
CN101161117A (zh) | 具有降血压和改善心脑血管功能的营养保健品及制备方法 | |
CN105112265A (zh) | 一种保健无花果酒及其制作方法 | |
CN1911102B (zh) | 解酒保健组合物及其生产方法 | |
JP2002233331A (ja) | 血行障害の改善作用を有する健康補助食品 | |
CN107751993A (zh) | 一种抗疲劳膏滋及其制备方法 | |
CN103222621B (zh) | 补益机体抗氧化保健品 | |
CN108576512A (zh) | 一种铁皮石斛复合饮料 | |
CN1680533A (zh) | 一种功能型含酒精液体的生产方法 | |
CN104922611B (zh) | 一种治疗心律失常的中药组合物及其制备方法 | |
CN105296288A (zh) | 一种罗汉果柚子果酒 | |
CN105797056A (zh) | 一种辅助缓解妇科疾病的保健品的组合物 | |
CN106032500A (zh) | 一种保健养生酒及制备方法 | |
CN104782830A (zh) | 一种养生保健茶及其配方 | |
CN107712890A (zh) | 一种宁心安神膏滋及其制备方法 | |
CN104106826B (zh) | 一种红景天饮料及其制备方法 | |
CN102579688B (zh) | 菊麻降压中药制剂 | |
CN101590097A (zh) | 一种降血压、降血脂和改善睡眠的中草药配方 | |
CN110935002A (zh) | 具有降血压功效的组合物及其应用 | |
CN1306765A (zh) | 三七速溶葛粉及其制备方法 | |
CN108420072A (zh) | 一种辅助降血压的复合特膳营养食品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161109 |